Zai Lab's stock surged 5.94% during intraday trading on Thursday, following the announcement of a significant global clinical research collaboration.
The biopharmaceutical company has entered into a partnership with Amgen to evaluate Zai Lab's clinical-stage antibody-drug conjugate, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA therapy for the treatment of patients with extensive-stage small cell lung cancer. Under the agreement, Amgen will sponsor a global Phase 1b study, while Zai Lab retains full ownership of its investigational drug and will supply it for the clinical trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments